BeOne's Brukinsa plus rituximab cut disease progression risk by 43% versus chemoimmunotherapy in a Phase 3 frontline mantle cell lymphoma trial.
June 30, 2026 06:00 AM EDTUpdated 06:26 AM
R&DPharma
BeOne’s Brukinsa succeeds in frontline mantle cell lymphoma study
Lei Lei Wu
News Reporter
A Brukinsa regimen has delivered a large progression-free survival (PFS) benefit in what BeOne Medicines called a “new…
BeOne Medicines reported positive Phase 3 BRUKINSA data in mantle cell lymphoma, reducing progression or death risk by 43% ahead…
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), un'azienda oncologica globale, oggi ha annunciato i risultati…
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
BeOne Medicines annuncia 'risultati positivi dello studio di fase 3 Mangrove in cui zanubrutinib, in associazione con rituximab,…
